Close

Gilead Sciences (GILD) Confirms U.S. FDA Granted Accelerated Approval to Trodelvy for Treatment of Metastatic Urothelial Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/26/2024

1. META
2. GOOGL
3. MSFT
4. SPY
5. CMG
6. LRCX
7. INTC
8. SNAP
9. IBM
10. BA


Go back to Gilead Sciences (GILD) Confirms U.S. FDA Granted Accelerated Approval to Trodelvy for Treatment of Metastatic Urothelial Cancer
Gilead Sciences (NASDAQ: GILD) Delayed: 65.27 --0 (-0%)
Previous Close $65.27    52 Week High $108.63 
Open $65.27    52 Week Low $71.39 
Day High $65.27    P/E 36.06 
Day Low $65.27    EPS $1.81 
Volume 105